Linda Stein Gold, MD

Considerations for Switching Treatment

Video content above is prompted by the following:

Would you consider a treatment switch in a patient with 75% improvement?

Videos

Panelists discuss whether a treatment switch would be considered for a patient with 75% improvement in atopic dermatitis, weighing the benefits of continued treatment versus the potential for further improvement with a different therapy.

Treatment Nonresponders in Atopic Dermatitis

How do you define treatment nonresponders in AD?

Panelists discuss how they define treatment non-responders in atopic dermatitis (AD), focusing on factors such as lack of significant improvement in symptoms, inadequate response to therapy, or failure to achieve treatment goals despite proper adherence and adjustments.

Lebrikizumab in Patients With Skin of Color (ADmirable)

AD is fairly common in patients with skin of color, but we have limited data with AD drugs in these patients.

Please discuss data from other studies, including any real-world data.

Panelists discuss the limited data on atopic dermatitis (AD) treatments in patients with skin of color, highlighting findings from other studies and real-world data to better understand treatment efficacy and safety in this diverse patient population.

Data With IL-13– Targeting Agents in Atopic Dermatitis in Clinical Practice

Can you talk about switching from dupilumab and other RWD with IL-13 agents in AD?

Panelists discuss switching from dupilumab to other IL-13 inhibitors in atopic dermatitis (AD), reviewing real-world data (RWD) on the effectiveness, safety, and patient outcomes associated with these treatments.

Linda Stein Gold, MD

Articles